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Summary. Mouse F9 embryocarcinoma (EC) cells 
constitute a well established cell-autonomous model 
system for investigating retinoid signaling in vitro as, 
depending on culture conditions, retinoic acid (RA) can 
induce their differentiation into either primitive, parietal 
or visceral extraembryonic endoderm-like cells. These 
RA-induced differentiations are accompanied by 
decreases in proliferation rates, modifications of 
expression of subsets of RA-target genes, and induction 
of apoptosis. To elucidate the roles played by the 
multiple retinoid receptors (RARs and RXRs) in 
response to RA treatments, F9 EC cells lacking one or 
severa1 RARs or RXRs were engineered through 
homologous recombination. Mutated RARs and/or 
RXRs were then reexpressed in given RAR or RXR null 
backgrounds. WT and mutant cells were also treated 
with different combinations of ligands selective for 
RXRs and/or for each of the three RAR isotypes. These 
studies lead to the conclusion that most RA-induced 
events (e.g. primitive and visceral differentiation, growth 
arrest, apoptosis and activation of expression of a 
number of genes) are transduced by RARy/RXRa 
heterodimers, whereas some other events (e.g. parietal 
differentiation) are mediated by RARa/RXRa  
heterodimers. They also demonstrate that both AF-1 and 
AF-2 activation functions of RARs and RXRs, as well as 
their phosphorylation, are differentially required in these 
RA-induced events. In RARy/RXRa heterodimers, the 
phosphorylation of RARy is necessary for triggering 
primitive differentiation, while that of RXRa is required 
for growth arrest. On the other hand, phosphorylation of 
RARa is necessary for parietal differentiation. Thus, 
retinoid receptors are sophisticated signal integrators that 
transduce not only the effects of their cognate ligands, 
but also those of ligands that bind to membrane 
receptors. 
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lntroduction 
Retinoids, mainly retinoic acid (RA), the 
biologically active metabolite of Vitamin A (retinol), 
play crucial roles in a wide variety of biological 
processes including embryonic morphogenesis and 
organogenesis, cell proliferation, differentiation and 
apoptosis, homeostasis, as well as in their disorders (e.g. 
malignant transformation) (Blomhoff, 1994; Gudas et 
al., 1994; Sporn et al., 1994; Kastner et al., 1995). These 
pleiotropic effects are mediated through two classes of 
nuclear ligand-dependent transcriptional regulators, the 
three Retinoic Acid Receptor isotypes (RARa, B and y 
and their isoforms) and the three Retinoid X Receptor 
isotypes (RXRa, B and y and their isoforms). In vitro 
studies, performed with either cell-free systems or 
cultured cells cotransfected with vectors overexpressing 
the various retinoid receptors and recombinant reporter 
genes indicated that RARs and RXRs bind as RARIRXR 
heterodimers to response elements (RES) of RA- 
responsive genes (Leid et al., 1992; Glass, 1994; 
Mangelsdorf and Evans, 1995; Mangelsdorf et al., 1995; 
Chambon 1996, and references therein). They also 
allowed the dissection of the transcriptional role of the 
different retinoid receptor domains (Nagpal et al., 1992, 
1993; Folkers et al., 1993; Durand et al., 1994) and of 
their phosphorylation (Rochette-Egly et al., 1997; 
Bastien et al., 2000). However, such studies are far from 
physiological conditions both in terms of receptor 
concentrations and responsive reporter genes. 
In vivo genetic analyses in the mouse also supported 
the conclusion that RAR/RXR heterodimers are the 
functional units transducing the retinoid signal in vivo 
(Kastner et al., 1995, 1997; Mascrez et a1.,1998). 
However, the interpretation of such studies could be 
equivoca1 at the molecular level, due to difficulties in 
RAR and RXR activation functions and phosphos/lation in F9 cells response to RA 
discriminating between cell-autonomous and non-cell- 
autonomous events in the intact animal, and to possible 
functional redundancies between receptor isotypes. 
These in vitro and in vivo difficulties for 
investigating the functional specificity of the different 
retinoid receptors led us to choose the F9 murine 
embryonal carcinoma (EC) cell line as a cell- 
autonomous model system for analysing retinoid 
signaling, under conditions which mimick, at least to 
some extent, physiological processes occurring during 
early embryogenesis. Indeed, upon RA treatment, and 
depending on the culture conditions, the F9 EC cell line 
differentiates into cells resembling either one of the three 
distinct extraembryonic endoderms (primitive, parietal 
and visceral) (Fig. 1) (for review, see Strickland, 1981; 
Hogan et al., 1983; Gudas et al., 1994). Retinoid- 
induced differentiation of F9 cells is accompanied by a 
decrease in proliferation rate (anti-proliferative 
response) (Clifford et al., 1996, and referentes therein), 
triggering of apoptosis and RA-induced variations in 
expression of subsets of responsive genes (Clifford et al., 
1996; Chiba et al., 1997b). Importantly, F9 EC cells 
express al1 RAR and RXR isotypes, with RARal and 
RARy2 being the main RAR isoforms (Zelent et al., 
1989; Wan et al., 1994; Taneja et al., 1995). Upon RA 
treatment, F9 cells also express the RARB2 isoform, due 
to activation of the RARB2 gene promoter which 
contains a RA-responsive element (de Thé et al., 1990; 
Hu and Gudas, 1990; Taneja et al., 1995). 
l k o  strategíes have been used to investigate the 
possible role played by the various RARs and RXRs in 
the responses of F9 EC cells to RA treatment. Firstly, the 
genes for either RARa, RARy, RAiU32 or RXRa were 
disrupted by homologous recornbination (Boylan et al., 
1993, 1995; Clifford et al., 1996, Faria et al. 1999). Cells 
lacking both RARy and RXRa, or both RARa and 
RXRa, were also engineered (Chiba et al., 1997a,b). 
Secondly, wild type (WT) and mutant F9 cells were 
treated with pan-RXR- and RAR isotype (a, B or y) - 
selective retinoids (Roy et al., 1995; Taneja et al., 1996; 
1997; Chiba et al., 1997a,b). Then, to investigate the 
possible specific role of the activation functions of 
RARa, RARy and RXRa, and of their phosphorylation 
in the retinoid-induced events, "rescue" cell lines 
reexpressing WT or mutant receptors were derived from 
RARa, RARy or RXRa null cells (Taneja et al., 1997; 
Plassat et al., 2000; Rochette-Egly et al., 2000). 
This review describes how these strategies 
established which RAR/RXR heterodimers are involved 
in most RA-induced cellular events. It also illustrates 
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RAR and RXR activation functions and phosphorylation in F9 cells response to RA 
how the "rescue" lines provided an attractive system to 
analyze the contribution of the different activating 
domains. of RARs and RXRs, and of their 
phosphorylation in the events controlled by retinoids. 
The basics of retinoid signaling 
The retinoid signal is transduced by two families of 
nuclear receptors, the RARs and the RXRs, each 
consisting of three isotypes (a, 1i and y) encoded in 
separate genes (Leid et al., 1992; Chambon, 1996). 
RARs are activated by all-trans retinoic acid and its 9 4 s  
isomer, while RXRs are only activated by 9-cis RA. For 
each isotype, there are at least two main isoforms which 
are generated by differential promoter usage and 
alternative splicing and differ only in their N-terminal 
regions (Leid et al., 1992; Mangelsdorf et al., 1995; 
Chambon, 1996). 
RARs and RXRs are characterized by severa1 
modular domains designated A to F (see Fig. 2) (Leid et 
al., 1992; Chambon, 1996). The highly conserved region 
C corresponds to the core of the DNA-binding domain 
(DBD). Region E is functionally complex as it contains 
the ligand-binding domain (LBD), the ligand-dependent 
transactivation function AF-2, a dimerization domain, 
and also a silencing domain in the case of RARs. The 
activity of AF-2 is dependent on the integrity of a highly 
conserved amphipatic helix, the AF-2AD core that 
corresponds to helix 12 at the C-terminal end of the LBD 
(Durand et al., 1994; Mangelsdorf et al., 1995; 
Chambon, 1996). Ligand binding induces a major 
structural change in the conformation of helix 12 which 
creates a new surface for coactivator binding (Bourguet 
et al., 1995; Renaud et al., 1995; Wurtz et al., 1996; 
Moras and Gronemeyer, 1998; Egea et al., 2000 and 
references therein). The amino-terminal A/B region 
contains a ligand-independent transcriptional activation 
function AF-1 (Nagpal et al., 1992, 1993). The B region 
is conserved among the three RAR isotypes, but the 
amino-terminal A region is different for each isoform of 
a given RAR isotype (Leid et al., 1992). For a given 
RAR, the AF-1 and AF-2 activities synergize and exhibit 
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Fig. 2. Modular structure and functional organization of mouse retinoid receptors with particular emphasis on the activation 
The amino acid sequence of the phosphorylation sites located in the N-terminal region of RARa, RARO, RARy and 
phosphorylated serines are marked by an asterisk. The PKA sites present in the LBD are also shown. 
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some specificity that is dependent on both the cell type 
and the promoter-context of RA-responsive genes 
(Nagpal et al., 1992, 1993). The F region is absent in 
RXRs and its role in RARs, if any, is still unknown. 
Like several members of the nuclear receptor 
superfamily, RARs and RXRs are phosphoproteins 
(Rochette-Egly et al., 1991, 1992; Gaub et al., 1992). 
The AF-1 domain contains several potential 
phosphorylation sites for proline-directed kinases which 
include the cyclin-dependent kinases (cdks) and the 
Mitogen-Activated Protein Kinases (MAPKs) (Morgan, 
1997; Garrington and Johnson, 1999; Schaeffer and 
Weber, 1999). RARa and RARy can be "constitutively" 
(Le. in the absence of RA) phosphorylated in this region 
by the cyclin H-dependent kinase cdk7 associated to 
TFIIH (Rochette-Egly et al., 1997; Bastien et al., 2000), 
a general transcription factor also involved in DNA 
repair (Frit et al., 1999, and references therein). This 
phosphorylation which concerns serine 77 in RARal, 
serines 77 and 79 in RARyl and serines 66 and 68 in 
RARy2 (see Fig. 2), results from a retinoid-independent 
interaction with cdk7 and the core of TFIIH (see Fig. 3), 
and modulates the transcriptional properties of RARs in 
a promoter-context-dependent manner. RARB2 is also 
phosphorylated at similar residues (serines 67 and 70 in 
Fig. 2), but whether this receptor is phosphorylated by 
cdk7 remains to be determined. RARa and RARy are 
also phosphorylated by Protein Kinase A at an additional 
residue located at the C-terminal end of region E (serine 
369 in RARal  and serine 360 in RARy2) (Fig. 2) 
(Rochette-Egly et al., 1995). Finally, R X R a l  is  
constitutively phosphorylated in its N-terminal A region 
at serine 22 (Fig. 2), and can be hyperphosphorylated 
upon UV-activation of Stress-Activated Protein Kinases 
(SAPKs), namely the C-Jun N-terminal Kinases (JNK1 
and JNK2) at three residues in this A/B region (S61, S75 
and T87) and at one residue at the N-terminal end of the 
LBD (S265) (Adam-Stitah et al., 1999). 
RARs and RXRs bind as RAR-RXR heterodimers to 
cognate DNA response elements (Fig. 4), which are 
composed of two directly repeated half sites 
[puG(G/T)TCA motif] with a spacing of 5 bp (DR5 
RARE Chromtln TeRy>lít. 
Flg. 3. Transcnption by RAWRXR heterodimers requires both RAR AF- 
1 phosphorylation by TFIIH, and coactivator recruitment upon ligand 
binding. In F9 cells, a fraction of RAWRXR heterodimers is associated 
with the general transcription factor TFllH and the cdk7 subunit of TFllH 
phosphorylates the RAR AF-1 ninction. Upon ligand binding, RAWRXR 
heterodimers bound to a RA response elernent (RARE) recruit 
coactivators (plws, CBPlp300, etc) which allow remodelling of the 
ohrornatin ternplate through histone acetylation. 
elements), 2 bp (DR2 elements) or 1 bp (DR1 elements) 
(Leid et al., 1992; Mangelsdorf et al., 1995; Mangelsdorf 
and Evans, 1995). However, RXRs also bind to DR1 
elements as homodimers, and heterodimerize not only 
with RARs, but also with several other nuclear receptors 
such as the Thyroid Hormone Receptors, the Vitamin D 
Receptor, the Peroxisome Proliferator Activated 
Receptors (PPARs), the Liver X Receptor (LXR), the 
Farsenoid Receptor (FXR), and a number of orphan 
receptors (Mangelsdorf et al., 1995; Mangelsdorf and 
Evans, 1995; Chambon, 1996; Giguére, 1999; Willy and 
Mangelsdorf, 1999). Binding of the ligand converts 
RARJRXR heterodimers into strong transcriptional 
activators, a process that is accomplished by the release 
of corepressors and the subsequent association with a 
new set of proteins that function as transcriptional 
coactivators (Chambon, 1996; Moras and Gronemeyer, 
1998; Glass and Rosenfeld, 2000). This results in a 
transcriptional competent nuclear receptor linked to the 
transcriptional machinery and the chromatin template 
(see Fig. 3). In this process, the ligand-dependent 
activity of RXR is subordinated to that of liganded RAR 
(Apfel et al., 1995; Roy et al., 1995; Botling et al., 1997; 
Minucci et al., 1997; Vivat et al., 1997; Willy and 
Mangelsdorf, 1999). 
Finally, the ubiquitin-proteasome pathway appears to 
play a crucial role in the regulation of intracellular levels 
of a wide range of regulatory proteins, including nuclear 
receptors and other transcriptional activators, implicated 
in the control of key cellular functions, such as cell cycle 
progression, signal transduction, cell differentiation and 
cell death (Molinari et al., 1999; Thomas and Tyers, 
2000, and references therein). As RARs and RXRs are 
degraded through this pathway (Zhu et al., 1999; Kopf et 
al., 2000), the ubiquitin-proteasome pathway might 
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Flg. 4. Retinoic acid response elernents (RAREs) of RA-target genes. 
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RARyIRXRa heterodimers are functional unlts 
mediating RA-induced differentiation, growth arrest 
and target gene expression in F9 cells 
Primitive and parietal endodermal differentiation 
RA induces the differentiation of F9  cel ls  in 
monolayer culture (Strickland and Mahdavi, 1978), 
resulting in the formation of primitive endoderm-like 
cells exhibiting a characteristic flat and triangular 
morphology (Fig. 1). Addition of cyclic AMP along with 
RA results in the formation of parietal endoderm-like 
cells (Strickland et al., 1980; Weiler-Guettler et al., 
1992) which have a rounded and refractile auuearance 
. A (Fig. '1). 
F9 cell differentiation into mimitive endodermal 
cells can be also induced by a k y - s e l e c t i v e  agonist. 
Moreover, a combination of the RARy ligand present at 
a concentration low enough to be inactive on its own and 
of a pan-RXR-selective agonist, synergistically induces 
primitive endodermal differentiation (Roy et al., 1995; 
Taneja e t  al., 1997). However, addition of cAMP 
together with the RARy-selective ligand, either alone or 
combined with the pan-RXR agonist, does not trigger 
parietal endodermal differentiation and the cells retain a 
primitive endoderm-like morphology (Taneja et al. 
1997). The RARa-selective agonist either on its own or 
with cAMP, does not induce either, primitive or parietal 
endodermal differentiation, irrespective of the presence 
of the pan-RXR agonist. However, parietal endodermal 
differentiation occurs upon activation of both RARy and 
RARa together with cAMP (Taneja et al., 1997). This 
synergism between the RARy and RARa ligands was 
further enhanced upon concomitant activation of RXR. 
No or very little differentiation of F9 cells could be 
triggered by a RARB-selective agonist alone or  
associated with the pan-RXR agonist (Taneja et al., 
1996). Thus, RARyIRXRa heterodimers appear to 
mediate the events  required for  RA-induced 
differentiation into primitive endodermal cells, while 
RARaIRXRa heterodimers would play an importan1 
role in parietal endodermal differentiation in the 
presence of RA and cAMP. Although the activation of 
RARy and RARa does not require a strict temporal 
order, the formation of primitive endodermal cells 
always precedes the appearance of parietal endoderm- 
like cells (Taneja et al., 1997). Thus, differentiation into 
primitive endoderm could be a prerequisite for parietal 
endodermal differentiation. 
The pan-RXR ligand alone has no effect on F9 cell 
differentiation (Chiba et al., 1997b; Taneja et al., 1997), 
in agreement with the previous proposals that RXR 
agonists alone are unable to activate RARJRXR 
heterodimers unless the RAR partner is itself liganded. 
Thus the RXR activity is subordinated to that of its RAR 
partner, as is the case in transfected celis (see above for 
references). 
The above conclusions were definitely confirmed by 
knocking out the RARy, RARa,  RARB2 and RXRa 
genes. Knockout of either the RARy gene (al1 isoforms) 
(Boylan et al., 1993) or the RXRa gene (Clifford et al., 
1996), drastically impairs  primitive and parietal 
differentiation. However, RARa gene knockout has 
milder and more restricted effects, as RAR~-1- cells 
differentiate as efficiently as WT cells into primitive 
endoderm-like cells (Boylan et al., 1995) and are only 
delayed in parietal endodermal differentiation, as the 
corresponding morphology appeared at 120h instead of 
96h (Taneja et al., 1997; Rochette-Egly et al., 2000). F9 
cel ls  lacking both R A R a  and R X R a  st i l l  poorly 
differentiate into primitive and parietal endodermal cells, 
as  do RXRQ-1- cells. However, the double R A R ~ - / -  
/RXR~-1- mutant cells are completely defective for the 
two types of endodermal differentiations (Chiba et al., 
1997b). Surprisingly, F9 cells lacking RARB2 did not 
exhibit a typically differentiated morphology (Faria et 
al., 1999). In fact, as most of the RA-responsive genes 
that were studied were RA-induced in the RARB-1- cells 
following RA treatment, albeit at reduced levels, it has 
been suggested that RARB does not mediate the initial 
events in the RA-induced differentiation process, but 
instead would be required to achieve maximum 
induction (Faria et al., 1999). In other words, in F9 cells, 
the initial response to RA would be mediated via 
RARyJRXRa heterodimers, but the subsequent large 
increase in RARB2 (which occurs after 16-24 hours of 
RA exposure) would be required for maximal 
morphological and molecular responses (Faria et al., 
1999). 
Visceral endodermal differentiation 
When F9 cel ls  are grown in suspension a s  
aggregates (Fig. l), low levels of RA induce a visceral 
endodermal phenotype in the outmost-layer of the cells 
resulting in an irregular surface (Strickland, 1981). 
Similarly to primitive endodermal differentiation, 
visceral endodermal differentiation also appears to be 
mediated by RARyJRXRa heterodimers, as  it is  
synergistically induced by a combination of RARy- 
selective and pan-RXR-selective agonists at suboptimal 
concentrations (Chiba et al., 1997b). Additionally, 
although RXR~-1- cells diffferentiate efficiently (Clifford 
et al., 1996), RAR~- / -  cells are delayed for visceral 
differentiation, and in RAR~-/-/RXR~-/- cells, the surface 
of the aggregates remains as smooth as in untreated 
controls (Chiba et al., 1997b). However, both RAR~-1- 
and double R A R ~ J - / R x R ~ - / -  mutant cell aggregates 
still differentiate into visceral endodermal cells (Chiba et 
al., 1997b). Thus, it appears that in contrast to primitive 
and parietal differentiation, RARy/RXR(B+y) 
heterodimers can efficiently mediate visceral 
differentiation (Chiba et al., 1997b). 
Growth arrest 
Retinoid-induced differentiation of F9 cells is also 
RAR and RXR activation functions and phosphorylation in F9 cells response to RA 
accompanied by a decrease in the proliferation rate (anti- 
proliferative response), with a diminished rate of DNA 
synthesis and an increase in the fraction of cells in the 
G1 phase of the cell cycle (Clifford et al., 1996, and 
references therein). The functional units mediating the 
antiproliferative action of RA are also RARylRXRa 
heterodimers as only a RARy-selective agonist 
combined to a pan-RXR-selective one was able to inhibit 
proliferation (Chiba et al., 1997b). Moreover, a 
substantial reduced antiproliferative response to RA was 
observed in R X R ~ - 1 -  cells (Clifford et al., 1996) and 
R A R ~ - / - / R X R ~ J -  cells were completely defective for 
growth arrest (Chiba et al., 1997b). Surprisingly, 
RARB~-1-  cells did not efficiently arrest growth in 
response to RA (Faria et al., 1999). In fact, in this cell 
line, the reduced antiproliferative response has not been 
attributed to the absence of RAR132, but to lower levels 
of RXRa than in WT F9 cells (Faria et al., 1999), 
resulting in lower amounts of the active RARyIRXRa 
heterodimer. 
Activation of RA target genes 
In F9 cells, a number of RA-responsive genes, such 
as Hoxa-1, HNF3a, HNFlB, Stra4 and Stra6 which 
contain RAREs in their promoter, are controlled by 
RARylRXRa heterodimers (Taneja et al., 1996; Chiba et 
al., 1997a; Plassat et al., 2000; Rochette-Egly et al., 
2000). In RARyIRXRa pairs, both partners cooperate to 
activate transcription of these RA target genes, since a 
combination of the pan-RXR-selective ligand and of the 
RARy-selective one at concentration low enough to be 
inactive on its own, synergistically induced their 
expression in a dose-dependent manner (Taneja et al., 
1996; Chiba et al., 1997a). In contrast, RARa- and 
RARB-selective agonists have little or no effect when 
combined with the pan-RXR agonist. Moreover, the 
induction of these genes, which is reduced in RXR~-1- 
and RAR~-/- cells (but not in RAR~-1- cells) (Clifford et 
al., 1996; Chiba et al., 1997a; Tane'a et al., 1997), is 
abrogated in double RARyi-IRXRa-j- mutant cells and 
not significantly further affected in RAR~- / - /RxR~- / -  
cells (Chiba et al., 1997a). 
It must be noted that the activation of some other 
RA-target genes, although controlled by RARyIRXRa 
pairs, is more complex. As an example, Hoxb-1 is  
activated by both RARyIRXRa and RARaIRXRa 
heterodimers, as its expression is only slightly affected 
in RARY-1- and ~ ~ ~ c r - 1 -  cells (Plassat et al., 2000; 
Rochette-Egly et al., 2000), and is nearly abolished in 
cells doubly mutated for RXRa and either RARa or 
RARy (Chiba et al., 1997a). In contrast, the induction of 
Stra8 is preferentially mediated by RARyIRXR @+y) 
pairs, since it is reduced in R A R ~ - / -  cells, but not in 
R X R ~ - 1 -  cells and is  not abrogated in the double 
R A R ~ - / - / R x R ~ - / -  mutant cells (Chiba et al., 1997a). 
Moreover, both the RARy- and RARa-select ive 
retinoids, have very little effect on the expression of 
Hoxb-1 (Plassat et al., 2000; Rochette-Egly et al., 2000), 
but their combination induces Hoxb-1 expression as 
efficiently as does RA (Chiba et al., 1997a). Finally, the 
activation of RARB2 has been shown to be mediated by 
multiple RAR ( a ,  B, y)/RXR ( a ,  B, y) pairs. In this 
respect,  although preferentially induced by a 
combination of RARy- and pan-RXR-selective agonists 
(Taneja et al., 1996), RARB2 activation is not affected in 
either R A R ~ - / -  or R A R ~ - / -  cells. In fact, it is onl 
slightly decreased in R X R ~ - "  and RARa-1-IRXRa-Y 
cells, and further reduced (but not abrogated) in RAR~J' 
/RXR~-1- cells (Chiba et al., 1997a). 
Al1 these data support the conclusion that in F9 cells, 
RARIRXR heterodimers are the functional units 
transducing the retinoid signal, and indicate that distinct 
RARIRXR isotype combinations are preferentially 
involved in the various RA-induced cellular events. 
Interestingly, in F9 cells, RARyIRXRa heterodimers are 
also targets for the ubiquitin proteasome pathway, since 
both RARy and R X R a  (and not RARa)  are 
ubiquitinylated and degraded following a treatment with 
RA (Kopf et al., 2000), or a combination of RARy- and 
pan-RXR-selective agonists at suboptimal 
concentrations (Kopf E., Chambon P. and Rochette-Egly 
C., unpublished observations). Since RARylRXRa 
heterodimers are the main RA transducers in F9 cells, 
playing a key role in the induction of most endogenous 
RA-responsive genes and in the initiation of the 
differentiation processes, it has been proposed that the 
ubiquitin-proteasome pathway provides a mechanism for 
negative feedback regulation of RA action (Kopf et al., 
2000). 
Redundancies between RARs and RXRs can be 
artefactually generated by gene knock-outs in F9 
cells 
According to the studies summarized above, 
RARyIRXRa heterodimers are involved in most RA- 
induced events in F9 cells. Moreover, a number of these 
events, e.g. primitive endodermal differentiation, appear 
to be mediated only by this pair, as RARy andlor RXRa 
gene knockouts are not compensated by possible 
functional redundancies among RARsIRXRs 
heterodimers. However, in other cases, gene knockouts 
appear to generate artefactual conditions unmasking 
potential functional redundancies which are not present 
in WT conditions. In other words, in these cases, 
suppression or mutation of one RAR or RXR can be 
functionally compensated by other RARs or RXRs. 
For example, in RAR~-/- cells, the RARBIpan-RXR 
and RARaIpan-RXR-selective agonist combinations, 
which have little or no effect on WT F9 cells, trigger 
visceral differentiation and inhibit proliferation of 
RAR~-/- cells (Chiba et al., 1997b). Thus, RARa andlor 
RARO can replace RARy in these RA-induced events. 
Moreover, the induction of certain RA-target genes such 
as Hoxa-1, Hoxb-1 and RARB2 b the RARa-selective T agonist is much stronger in RARy- cells, indicating that 
to some extent, the presence of RARy prevents RARa 
RAR and RXR activation functions and phosphorylation in F9 cells response to RA 
from mediating these inductions (Taneja et al., 1996; 
Plassat et al., 2000). 
R A R a  knockout also generates artefactual 
conditions, as RARy could substitute for RARa in 
R A R ~ - / -  F9 cells. RARy activation with a selective 
agonist, can indeed brin about a delayed parietal F differentiation of RARa- cells, whereas it does not 
result in any parietal differentiation in WT F9 cells 
(Taneja et al., 1997). In addition, in the absence of 
RARa, the RARy-selective ligand is more efficient for 
inducing growth arrest (Chiba et al., 1997b) or some 
RA-target genes, such as Hoxa-1, Hoxb-1, Stra6 and 
RARB2 (Taneja et al., 1996; Chiba et al., 1997a; 
Rochette-Egly et al., 2000). 
Functional redundancies occur not only among 
RARs, but also among RXRs, as the pan-RXR-selective 
agonist in combination with the RARy one can trigger 
efficiently visceral differentiation of R X R ~ - 1 -  and 
R A R ~ - / - / R x R ~ - / -  cells (Chiba et al., 1997b). This 
combination also synergistically induces the expression 
of the RARB2 gene in RAR~-/- /RxR~-/-  cells (Chiba et 
al., 1997a). Reciprocally, in agreement with the 
inducibility of the RAR132 gene by multiple RARIRXR 
pairs, the pan-RXRIRARa agonist combination was 
efficient in RAR~-/-/RxR~-/- cells (Chiba et al., 1997a). 
Thus, in certain RA-induced cellular events, the other 
RXR isotypes (RXRB and RXRy) can substitute for 
RXRa in cells lacking RXRa. How the presence of a 
RXRIRAR heterodimer prevents other potentially 
functionally redundant heterodimers from transducing 
the RA signal is unknown, but it could be related to their 
differential affinities for the RAREs of the target genes. 
Surprisingly, these studies also revealed that the 
proliferation of mutant cells lacking both RARy and 
RXRa was increased by RARa and RARB agonists 
combined with the pan-RXR agonist (Chiba et al., 
1997b). Thus, either RARalRXR @+y) or RARBIRXR 
@+y) heterodimers can mediate a proliferative effect of 
RA in the absence of RARy and RXRa.  Note that 
induction of proliferation of certain cell types by 
retinoids has been reported (Koshimizu et al., 1995). 
In conclusion, in F9 cells, gene knock-out can 
generate artefactual conditions in which ablation of a 
given RAR or RXR can be functionally compensated by 
the other RARs or RXRs. Interestingly, in some events 
such as cell proliferation, the activation of the other 
RARIRXR heterodimers can induce opposite effects. 
Both AF-1 and AF-2 Activation Functions of RARy, 
RARa and RXRa are necessary for the response of 
F9 cells to RA 
To dissect the functional roles of the ligand- 
independent activation functions AF-1 and AF-2 in RA- 
induced cellular events, "rescue" lines stably expressing 
RARy, R A R a  or R X R a  lacking these AFs were 
established, starting from a null background (Fig. 5). As 
the various responses of F9 cells to RA could also be 
restored in RARY-1- cells by overexpressing RARa 
(Taneja et al., 1995), rescue lines overexpressing WT or 
mutant RARa were also established. 
This strategy allowed us to demonstrate that the AF- 
1 activating domain of RARs is required to transduce the 
RA signal (Taneja et al., 1997; Rochette-Egl et al., ? 2000) (see Table 1). Indeed, in RARy- cells,  
reexpression of RARy lacking the AF-1-containing N- 
terminal region (RARyAAF-1) does not restore primitive 
endodermal differentiation and the subsequent parietal 
differentiation. The same results were obtained with 
overexpressed RARaAAF-1. Similarly, RARaAAF-1 
was unable to restore parietal differentiation in RAR~-1- 
cells. In fact, this deletion mutant behaved as a dominant 
negative, as it abrogated the primitive differentiation of 
RAR~-1- cells (Rochette-Egly et al., 2000). 
To determine whether the same phenomenom occurs 
"rescue" lines rwxp 
RARyWT m . : c I D  R A R a W i  
RXRaWT 
RARyAAF-1 1 c 1 D - RARa AAF-1 
RXRaAAF-1 
RARy AAF-2 : RARaAAF-2 
. -- -. . -. - -- 
RARy S66168A m C 1 D RARa S77A 
RARy S360A - a :  RARa S369A 
Primitlve and Parietal differentiation 
RXRcr" cells > 
+ 
le "rescue" Ilnes reexpres 
+ RA 
Growth arrest 
Flg. 5. Schematic representation of the mouse RAR and RXR mutants used to generate the various rescue iines. A. RARa and RARy rescue lines. 
B. RXRa rescue lines. 
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for visceral differentiation, RAR~-/-/RxR~-/- cells were 
rescued with either RARyWT or RARyAAF-1 (Kopf E., 
Chambon P. and Rochette-Egly C., unpublished results). 
As expected, reexpression of RARyWT restored full 
visceral differentiation. However, cells reexpressing 
RARyAAF-1 did not show any visceral differentiation at 
4 days. In fact, morphological differentiation appeared at 
10 days, indicating that this mutant brings about a 
delayed morphological differentiation. Altogether, these 
results indicate that the AF-1 domain is required for 
RARs to trigger F9 cell differentiation (Table 1). 
Interestingly, and in contrast to that was observed 
with RARs, RXRaAAF-1 rescued the differentiation of 
RXR~-1- cells as efficiently as RXRaWT (Clifford J., 
Chiba H., Metzger D. and Chambon P., unpublished 
results). However, the AF-1 activating domain of RXRa 
was found to be required for the antiproliferative effect 
of RA (Table 1) (Bastien J., Chambon P. and Rochette- 
Egly C., manuscript in preparation). Whether the AF-1 
domain of RARy also plays a role in this RA-induced 
cellular event has not been investigated as yet. 
Efficient expression of most RA-inducible genes 
also requires the AF-1 domain. For example, in RARy-1- 
cells, either RARyAAF-1 or overexpressed RARaAAF-1 
are unable to restore the activation of genes such as 
HNF3a, HNFlB and Stra6 (Taneja et al., 1997 and Table 
2). However, it must be noted that for other RA-target 
genes, the contribution of the AF-1 domain depends on 
the receptor isotype and on the promoter context. As an 
example, the induction of Hoxa-1 is unaffected by the 
deletion of the RARy AF-1-activating domain, whereas 
it is dependent on that of overexpressed RARa (Taneja 
et al., 1997). Interestingly, in M ~ a - 1 -  cells, where the 
activation of most genes is not altered, the same RARa 
deletion mutant behaves as a dominant negative with a 
promoter-context dependency (Rochette-Egly et al., 
2000 and Table 2). Whether the AF-1 activation domain 
of RXRa is important for the activation of RA-target 
genes remains to be determined. 
The same strategy demonstrated that the AF-2 
activating function of RARa, RARy and RXRa is also 
indispensible for the RA-induced cellular events (Table 
1). In this respect, neither RARy nor overexpressed 
RARa deleted for their AF-2AD core (Helix 12) could 
restore primitive and subsequent parietal differentiation 
of RAR~-/- cells (Plassat et al., 2000). Similarly, RARa 
deleted for this domain was unable to restore parietal 
endodermal differentiation in RAR~-1- cells (Rochette- 
Egly et al., 2000). These results are in agreement with 
the lack of differentiation of the RAC65 P19 EC cells 
which express a truncated form of RARa lacking the 
AF-2AD core (Pratt et al., 1990; Kruyt et al., 1992; 
Costa and Mc Burney, 1996). Finally, RXRa deleted for 
its AF-2AD core was also unable to restore the 
differentiation of R X R ~ - 1 -  cells at limiting ligand 
concentrations (Clifford J., Chiba H., Metzger D. and 
Chambon P., unpublished results). As yet, the role of the 
AF-2AD core of the two partners in RARyIRXRa 
heterodimers has not been studied for the 
antiproliferative action of RA. However, from the 
present data, it can be predicted that this motif 
contributes to the growth arrest induced by RA. Finally, 
the AF-2 of RARy and RARa is required for the 
efficient induction of al1 the tested genes, since 
RARyAAF-2 and overexpressed RARaAAF-2 are 
inefficient in restoring their inducibility in RAR~-I- cells 
(Plassat et al., 2000; Rochette-Egly et al., 2000 and 
Table 2). This is in accordance with previous reports 
Table 1. lnvolvement of the various RARs and RXRs in the transduction of the retinoid signal in F9 cells and role of their activation functions and 
phosphorylation sites 
RETINOID-INDUCED HETERODIME INVOLVED ACTIVATION FUNCTIONS AND PHOSPHORYLATION SlTES INVOLVED 
RARs RXRs 
Pnmitive Endodermal RARyIRXRa - RARy AF-1 and AF-2 (a, e) - RXRa AF-2 (9 
differentiation (in al1 instances) - RARy phosphorylation sites - No role for RXRa AF-1 and 
(a,b,c) in AF-1 (S66 and S68) (a) phosphorylation sites (9 
Panetal endodermal RARaíRXRa - RARa AF-1 and AF-2 (d) - RXRUAF-2 (9 
differentiation (a) 
- RARa PKA sRe (in the AF-2 - No role for RXRa AF-1 and 
- RARyIRXRa in the LBD) (d) phosphorylation site (9 
absence of RARa (a) 
- Primitive dierentiation 
is a prerequisite (a) 
RARy/RXR(a, fl, y) 
(b) 
- RAR(a,B)/RXRa in the 
absence of RARy (b) 
- RARy/RXR(B,y) in the 
absence of RXRa (b) 
RARyIRXRa - RXRa AF-1 (9 
(b) - RXRa phosphorylation in 
RAR(a,R)/RXRa in the AF-1 (S22) (9 
absence of RARy @) 
(a):Taneja et al., 1997; (b): Chiba et al., 1997b; (c): Clifford et al., 1996; (d): Rochette-Egly et al., 2000; (e): Plassat et al., 2000; (9: Unpublished results. 
- RARy AF-1 and AF-2 (9 
- RARy AF-1 and AF-2 (9 
- RARy phosphorylation sites 
in AF-1 (S66 and S68) (9 
Visceral endodermal 
difierentiation 
Growth arrest 
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showing that the AF-2 AD core motif is an essential 
element of the ligand-inducible activation function AF-2 
(Chambon, 1996) and cooperates with the AF-1 
activating domain (Nagpal et al., 1992, 1993). 
The study of the RARaAAF-2 and RARyAAF-2 
rescue lines also confirmed the previous in vitro 
observations which suggested that RARs deleted for 
their AF-2AD core behave as dominant negatives 
(Damm et al., 1993; Durand et al., 1994; Schulman et 
al. ,  1996). Indeed, in the RARY-/- background, 
RARyAAF-2 and to a lesser extent RARaAAF-2 
inhibited the residual activation of certain genes by 
RARa (Plassat et al., 2000). This was particularly clear 
i n  the case of Hoxb-1 (Table 2) and RARB2 whose 
induction can be mediated by either RARyIRXR or 
RARaIRXR heterodimers and is not affected in ~ ~ y - 1 -  
cells. Similar conclusions came from results with the 
same RARa mutants reexpressed in R A R ~ J -  cells where 
the induction of most RA-responsive genes is  not 
altered. Indeed, in these cells,  reexpression of 
RARaAAF-2 decreased the RA-induced expression of a 
subset of responsive genes (Rochette-Egly et al., 2000 
and Table 2). 
In conclusion, this "rescue" strategy allowed us to 
demonstrate that RARs need the integrity of both their 
AF-1 and AF-2 domains to efficiently transduce the 
retinoid signal. 
Role of RARa, RARy and RXRa phosphorylation. 
R A R a  and RARy are "constitutively" 
phosphorylated in a ligand-independent manner in their 
N-terminal AF-1 domain by cdk7 within TFIIH (see Fig. 
2). Since RARal and RARy2 are phosphorylated in F9 
cells, at one (S77) and two (S66 and S68) serine residues 
respectively (Rochette-Egly et al., 1997; Bastien et al., 
2000), the "rescue" strategy was also used to study the 
role of these phosphorylations in RA-induced cellular 
events. Stable rescue lines reexpressing RARa and 
RARy mutated at these phosphorylation sites 
(RARaS77A and RARyS66AIS68A cell lines) were 
established (Taneja et al., 1997; Rochette-Egly et al., 
2000) (Fig. 5A). 
Phosphorylation of serines 66 and 68 is mandatory 
for RARy to restore, in R A R ~ - / -  cells,  primitive 
endodermal differentiation and the subsequent parietal 
differentiation (Taneja et al., 1997). In contrast, for 
RARa, phosphorylation of serine 77 is not required to 
efficiently restore the parietal endodermal differentiation 
of RAR~-1-  cells (Rochette-Egly et al., 2000). Thus, 
phosphorylation of the AF-1 activation domain of RARy 
is required for primitive endodermal differentiation 
(Table l ) ,  while phosphorylation of the same residues in 
R A R a  does not appear to play a role in parietal 
differentiation. However, in RARY-I- cells,  
phosphorylation of overexpressed RARa was found to 
be mandatory for parietal endodermal differentiation, 
while it was not required to restore primitive endodermal 
differentiation at the morphological level (Taneja et al., 
1997). Interestingly, severa1 RA-responsive genes are 
not restored to WT levels in RARY-1- cells rescued with 
RARaS77A (see below). Thus, RARa phosphorylation 
Table 2. Relative expression of RA-responsive genes in RARy-1- and R A R ~ ' ~ '  cells and mutant rescue lines. 
F9 cell lines Hoxa-1 HNF3a HNF1 B Stra6 Hoxb-1 
- -  - 
WT 6.5 8.4 17.8 17.9 11.3 
RARy" 2.6 1.9 0.3 9.5 9.9 
RARa-1- 5.9 8.1 19.6 19.7 7.7 
RARy-1- rescued by RARy (a, b) 
RARy-WT 10.3 9.7 8.1 16.2 8.5 
RARy-MF-1 7.2 3.0 1 .O 2.0 ND 
RARy-S66168A 6.0 6.0 1 .O 18.0 ND 
RARy-S360A N D ND ND ND ND 
RARy-MF-2 0.2 0.17 0.33 0.5 0.7 
RARy-1- rescued by overexpressed RARa (a,b) 
RARaWT 10.4 8.1 1 11.2 19.4 7.4 
RARaAAF-1 4.0 2.0 2.0 4.0 ND 
RARaS77A 8.0 3.0 8.0 6.0 ND 
RARaS369A ND ND ND ND ND 
RARaAAF-2 4.25 0.56 0.33 6.6 4.45 
RARa-1- rescued by RARa (c) 
RARaWT 7.7 9.3 19.9 16.5 13.7 
RARaAAF-1 5.1 2.8 1.4 17.6 16.5 
RARaS77A 8.0 9.5 13.2 14.3 10.1 
RARaS369A 9.8 7.0 13.1 14.2 10.1 
RARaAAF-2 6.1 1 .8 1.2 9.9 13.1 
The relative level of induction of Hoxa-1, HNF3a, HNFl B, Stra6 and Hoxb-1 in each cell line grown in the presence of RA (100nM) for 24 hours was 
estimated by semiquantitative RT-PCR followed by quantification of the signals with a Bio-lmaging analyser. The results correspond to the fold 
induction relative to the amount of RNA transcripts present in ethanol-treated cells which was given an arbitrary value of 1. The values are an average 
of at least three experiments which agreed with t15%. (a): Taneja et al., 1997; (b): Plassat et al., 2000; (c): Rochette-Egly et al., 2000. 
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could be indispensible to efficiently rescue primitive 
endodermal differentiation, which is a prerequisite for 
subsequent parietal differentiation, whereas this 
phosphorylation would not be required for parietal 
differentiation per se. 
RARy is also unable to efficiently trigger visceral 
differentiation, unless it is phosphor lated in the N B  
region (Table 1) .  Indeed, RARy-TiRXRa-1- cells 
reexpressing RARyS66NS68A are delayed in visceral 
differentiation, as morphological differentiation appears 
at 10 days instead of 4 days (Kopf E. and Rochette-Egly 
C., unpublished results). 
RXRa is also "constitutively" phosphorylated, in a 
ligand-independent manner, in the AF-1-activating 
domain at serine 22 (Fig. 2). To determine the role of 
this phosphorylation, stable rescue lines reexpressing 
RXRa mutated at this phosphorylation site (RXRaS22A 
line) (Fig.  5B) were established in a R X R ~ - 1 -  
background. This cell line differentiates efficiently 
indicating that RXRa can mediate differentiation in the 
absence of serine 22  phosphorylation (Table 1) .  
However, this phosphorylation site is required for the 
antiproliferative response to RA (Bastien J., Chambon P. 
and Rochette-Egly C., manuscript in preparation). 
Whether RARy phosphorylation in its AF-1 domain also 
plays a role in the antiproliferative effect of RA and 
synergizes with RXRa phosphorylation to mediate the 
antiproliferative action of RA remains to be determined. 
Previous studies performed with cells cotransfected 
with reporter genes and plasmids expressing the retinoid 
receptors, either WT or mutated at their phosphorylation 
sites (RARaS77A and RARyS66/68A), suggested that 
phosphorylation of these residues by cdk7 is important 
for the transactivation properties of RARs, but with a 
promoter-context dependency(R0chette-Egly et al., 
1997; Bastien et al., 2000). Thus, it was important to 
determine whether similar results could be obtained with 
the various RA-target genes identified in F9 cells. By 
testing the inducibility of the RA-target genes in the 
R A R ~ - / -  rescue lines reexpressing RARyS66168A or 
overexpressing RARaS77A, the requirement for these 
phosphorylation sites was found to be promoter- 
dependent, and also receptor isotype-dependent (Taneja 
et al., 1997). As an example, phosphorylation of RARy 
is required for the efficient induction of HNFlB and to a 
lesser extent of HNF3a, but not for the other genes 
tested, while phosphorylation of overexpressed RARa is 
necessary for the induction of HNF3a and Stra6 (Table 
2). Thus, it would be interesting to determine whether 
phosphorylation of RXRa at serine 22 in the A/B region 
is important for the activation of certain RA target genes 
andlor cooperates with that of RARs. 
Finally, it has been demonstrated that the 
degradation of RARy by the ubiquitin-proteasome 
pathway requires phosphorylation of the receptor (Kopf 
et al., 2000). However, since cell lines reexpressing 
RARyS66AIS68A do not differentiate upon RA 
treatment, it cannot be concluded whether the defect in 
the degradation of this mutant receptor reflects the lack 
of phosphorylation or is a consequence of the absence of 
differentiation. 
RARy and RARa are also phosphorylated by PKA 
at a conserved residue located at the C-terminal end of 
the LBD (S360 for RARy2 and S369 for RARal ) .  
Phosphorylation of the PKA site of RARy was found to 
be dispensible for  both primitive and parietal 
differentiation. However, phosphorylation of this site in 
RARa is mandatory to rescue parietal differentiation 
either in RAR~-1- cells, or when overexpressed in RARy- 
1- cells (Taneja et al., 1997). Thus, it was concluded that 
phosphorylation of the PKA site of RARa is required for 
parietal differentiation (Table 1). However, none of the 
RA-responsive genes tested so far were found to be 
regulated by phosphorylation of RARs at their PKA site 
(Rochette-Egly et al., 2000). Studies are in progress in 
order to identify genes whose expression is sensitive to 
such phosphorylations. 
Conclusions and perspectives 
F9 cells represent an interesting autonomous cell 
system to study the molecular mechanisms underlying 
the complex biological events induced by retinoids, 
since they respond to retinoic acid by a morphological 
differentiation, a decrease in the proliferation rate and 
the activation of subsets of RA-target genes. Moreover, 
as F9 cells also respond to cyclic AMP, they constitute 
an excellent system to study crosstalk between the 
retinoid and other signaling pathways, including the 
PKA pathway. 
To elucidate the molecular mechanisms of retinoid 
signaling in this mammalian cell-autonomous system, 
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Flg. 6. In RA-treated F9 cells, the activation of most RA-target genes, 
the induction of primitive and visceral differentiation and the growth 
arrest involve RARyIRXRa heterodimers. In these heterodimers, the 
phosphorylation of AF-1 of RARy is required for the activation of ceriain 
genes and for triggering primitive and visceral differentiation, while that 
of RXRa is required for the antiproliferative action of RA. In contrast, the 
induction of parietal differentiation by RA and cAMP involves 
RARa/RXRa pairs and phosphorylation of the RARa partner at its PKA 
site. 
RAR and RXR activation functions and phosphorylation in F9 cells response to RA 
retinoid receptors were ablated by gene targeting and 
different combinations of specific ligands were used. By 
using these strategies, it has been demonstrated that 
RAR-RXR heterodimers are involved in the transduction 
of the retinoid signal, irrespective of the retinoid-induced 
event (cell differentiation, growth arrest or activation of 
RA-target genes), and that the activity of RXR is  
subordinated to that of its RAR partner. In WT F9 cells, 
most RA-induced cellular events, such as prirnitive and 
visceral differentiation, growth arrest or activation of 
most RA-target genes, are mediated by RARyIRXRa 
heterodimers (Fig. 6 and Table 1). However, some 
events such as parietal endodermal differentiation 
involve RARdRXRa pairs (Fig. 6 and Table 1). 
The idea that a specific RARIRXR heterodimer 
could be preferentially involved in mediating particular 
retinoid-dependent events has also been strongly 
supported by results of the RAR and RXR gene 
knockout studies performed in the mouse (Chambon, 
1994; Kastner et al., 1995, 1997; Mascrez et al., 1998, 
and references therein). However, the interpretation of 
the initial results was rather equivoca1 since mice lacking 
a single RAR isotype showed a limited number of 
defects, owing either to functional redundancies or to the 
difficulty to discriminate between cell-autonomous and 
cell-non autonomous effects. Therefore, by assuming 
that there are less functional redundancies between 
RARs in a RXRa mutant background, the role of a 
particular RXRaIRAR pair in a given function was 
determined in compound RARIRXRa mutants (Kastner 
et al., 1997; Mascrez et al.,. 1998). New strategies based 
on the creation of conditional spatio-temporally- 
controlled somatic mutations have been recently 
developed to bypass some of these problems (Li et al., 
2000, and references therein). In contrast, in F9 cells 
which are obviously less complex than the intact animal, 
single gene knockouts can generate unequivocal effects 
in a number of instances, although they may also result 
in artefactual conditions, unmasking potential functional 
redundancies which do  not occur in the wild-type 
situation. 
A complementary strategy was developed in F9 EC 
cells, with the aim of establishing the role of the 
Activation Functions and of the phosphorylation of 
RARs and RXRs in RA-induced events. This strategy is 
based on the reexpression of deleted o r  mutated 
receptors in either RARy-1-, RAR~- / -  or RXR~-1- cells. 
Studies performed with such F9 rescue lines support 
severa1 of the ideas that were previously suggested from 
in vitro studies, using cell-free systems or cultured 
transfected cells (see Table 1). 
First, the RARa, RARy and RXRa AF-2 AD core 
motifs contained in the LBD helix 12, are crucial for 
triggering endodermal differentiation and for activating 
most RA-target genes. This is in agreement with the 
capacity of this alpha amphipatic helix, an essential 
element of the AF-2 function, to recruit coactivators 
upon ligand binding, resulting in a transcriptionally 
competent receptor. Second, the Activating Function 
AF-1 also plays an important role, supporting the 
proposal that it could cooperate with AF-2. However, 
this role seems to differ from one receptor to another. 
For RARy, AF-1 is crucial for the induction of certain 
RA-target genes and for  triggering endodermal 
differentiation. For RARa, the result is puzzling, as this 
deletion mutant behaves as a dominant negative towards 
RARY 
The study of RARs and RXRa rescue cell lines also 
provides an attractive in vivo system to study how 
retinoid receptor phosphorylation is involved in the 
mechanism of retinoid signaling (see Fig. 6 and Table 1). 
Phosphorylation of RARy AF-1 domain by TFIIH 
appears to be necessary for the activation of certain RA- 
inducible genes and for triggering primitive and visceral 
endodermal differentiation. However, phosphorylation of 
the RXRa partner is not involved in the RA-induced 
differentiation of F9 cells, but is  required for the 
antiproliferative action of RA. How, in RARy-RXRa 
heterodimers, phosphorylation of each partner 
cooperates to activate the expression of RA target genes 
specifically involved in the differentiation andlor the 
growth arrest of F9 cells, remains to be seen. 
That phosphorylation of RARa by PKA upon cAMP 
addition to RA is required for parietal differentiation, 
demonstrates the existente of crosstalk between the RA 
and the PKA pathways for parietal differentiation, 
through the phosphorylation of RARa at its PISA site. 
As  the growth factor/Ras/MAPK cascade can 
phosphorylate in vitro the serine residues located in the 
AF-1 domain of RARs (Rochette-Egly et al., 1997; 
Bastien et al., 2000), F9 cells should provide an 
interesting system to determine whether 
hyperphosphorylation of these residues stimulates the 
AF-1 function and thus whether the MAPK cascade 
might cross-talk with the retinoid pathway, as is the case 
for the estrogen pathway (Kato et al., 1995; Bunone at 
al., 1996). Interestingly, hyperphosphorylation of RXRa 
by stress kinases has recently been shown to negatively 
modulate the activation of RA-target genes (Lee et al., 
2000). Future studies are required to determine whether 
and how R X R a  hyperphosphorylation by stress- 
activated kinases could suppress retinoid signaling in F9 
cells. 
The studies performed with WT and rescued F9 cells 
also show that the heterodimers which play a key role in 
RA-induced primitive differentiation and in the 
induction of expression of many RA-target genes (i.e. 
RARyIRXRa heterodimers), are  degraded by the 
ubiquitin-proteasome pathway and that this degradation 
depends on the phosphorylation of the RARy partner. 
Such results argue that transcriptional activation and 
activator degradation are closely coupled events. 
Therefore a model has been proposed (Kopf et al., 
2000), in which degradation mediated by the proteasome 
pathway may participate in the regulation of duration 
and magnitude of retinoid action. Upon ligand binding, 
RARyIRXRa heterodimers bound to cognate response 
elements recruit coactivators, leading to activation of 
RAR and RXR activation functions and phosphorylation in F9 cells response to RA 
transcription. A subsequent increase in ubiquitination 
would then result in the degradation of both 
heterodimeric partners. In this process, phosphorylation 
and ligand-dependent ubiquitination act in concert to 
trigger receptor degradation, thus modulating the 
intracellular levels of RARyIRXRa heterodimers and 
controlling the magnitude of the retinoid effect. 
In conclusion, through binding of cognate ligands 
and phosphorylation of their activation domains, retinoid 
receptors are highly sophisticated transducers, 
integrating signals belonging to severa1 signaling 
pathways. Thus, F9 cells and the mutants that we have 
generated, provide interesting tools to study complex 
physiological conditions that result from the integrative 
cross-talks of multiple signaling pathways. As different 
RARIRXR pairs have been shown to effect a given 
cellular event, in a cell-specific manner (Roy et al., 
1995; Chen et al., 1996), the question arises as to 
whether there is any principle governing the role of RAR 
and RXR phosphorylation in physiological responses to 
retinoids. Studies of the consequences of RAR and RXR 
phosphorylation should be extended to other mammalian 
cell lines such as P19 EC or APL NB4 cells whose 
differentiation involves RXRIRAR pairs different from 
those operating in F9 cells (Roy et al., 1995; Chen et al., 
1996). Finally, elucidating whether and how RAR and 
RXR phosphorylation is involved in the mouse during 
development and homeostasis is essential to reveal the 
physiological role of crosstalks between the retinoid 
signaling pathway and other signaling pathways that are 
ultimately mediated through phosphorylation of 
transregulators. 
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